Cyclo Therapeutics Q3 EPS $(0.29) Up From $(0.50) YoY, Sales $459.48K Beat $430.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Cyclo Therapeutics reported a narrower Q3 loss of $(0.29) per share compared to $(0.50) YoY, with sales of $459.48K exceeding estimates by 6.86% and showing a 1.62% increase from the previous year.
November 15, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cyclo Therapeutics reported improved Q3 earnings with a smaller loss per share and higher sales than expected, indicating potential positive momentum.
The reported earnings show a significant improvement in losses per share and a beat on sales estimates, which is likely to be viewed positively by investors. The year-over-year sales growth, although modest, along with the earnings beat, could lead to short-term bullish sentiment for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100